Immunovant, Inc. IMVT Total Operating Expenses
Total Operating Expenses at other companies
Other financials
Where this comes from
Reported directly by Immunovant, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The official record: Immunovant, Inc.’s 10-K, filed May 20, 2026, on SEC EDGAR. View the filing →
Ask your AI about Immunovant, Inc.'s total operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Immunovant, Inc.'s total operating expenses?
- Immunovant, Inc. (IMVT) reported total operating expenses of $159.55M in Q1 2026.
- How has Immunovant, Inc.'s total operating expenses changed year-over-year?
- Immunovant, Inc.'s total operating expenses increased by 40.2% year-over-year, from $113.83M to $159.55M.
- What is the long-term trend for Immunovant, Inc.'s total operating expenses?
- Over 4 years (2022 to 2026), Immunovant, Inc.'s total operating expenses has grown at a 35.9% compound annual growth rate (CAGR), from $156.03M to $532.9M.
- What does total operating expenses mean?
- The sum of all operating costs including COGS, SG&A, R&D, D&A, and other operating charges. Revenue minus total operating expenses equals operating income.